Paclitaxel Injection, Solution, Concentrate
Product Images NDC 0703-3217

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 0703-3217). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Parenteral Medicines, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 1)

Chemical structure of paclitaxel, showing its complex multi-ring molecular arrangement with functional groups including esters, hydroxyls, and aromatic rings, consistent with the active ingredient paclitaxel in the specified product.*

FDA Label Image

1 (Image 10)

Packaging label for Paclitaxel Injection USP 30 mg (6 mg/mL), a semi-synthetic source intravenous injection concentrate in a 5 mL multidose vial. Label indicates it is manufactured by Teva Parenteral Medicines, Inc. The label includes warnings about cytotoxicity, storage conditions, dilution requirement prior to IV use, and directions to dispense with a patient information leaflet. The label also displays the NDC 0703-3213-01 and a barcode.*

FDA Label Image

100 mg/16.7 mL Carton Image (Image 11)

Packaging label for Paclitaxel Injection USP 100 mg (6 mg/mL) in a 16.7 mL multidose vial by Teva Parenteral Medicines, Inc. The label indicates semi-synthetic source, concentration, dosage form as injection solution concentrate for intravenous use, warnings, storage instructions, and manufacturer details.*

FDA Label Image

150 mg/25 mL Carton Image (Image 12)

Packaging label for Paclitaxel Injection USP 150 mg (6 mg/mL) in a 25 mL multidose vial by Teva Parenteral Medicines, Inc. The semi-synthetic source drug label includes storage instructions, warnings about cytotoxicity, and dilution before IV use. Manufactured in the Netherlands and distributed by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

5 (Image 13)

Packaging label for Paclitaxel Injection USP, 300 mg (6 mg/mL), 50 mL multidose vial by Teva Parenteral Medicines, Inc. The label shows dosing strength, vial size, manufacturer details, and warnings including dilution required prior to IV use and handling precautions for this cytotoxic agent.*

FDA Label Image

Figure 1 (Image 2)

A survival curve graph showing proportion surviving over time in years for two groups labeled Cc and Tc, with a legend detailing sample sizes, number of events, and hazard ratio with confidence interval. The x-axis represents years from 0 to 5, and the y-axis shows proportion surviving from 0 to 1.*

FDA Label Image

Figure 2 (Image 3)

A Kaplan-Meier survival curve showing the proportion of subjects surviving over a 5-year period for two groups labeled 'Cc' and 'Tc'. The graph includes numbers at risk at various time points and a hazard ratio with confidence interval for comparison between groups.*

FDA Label Image

Figure 3 (Image 4)

A survival curve graph showing the proportion of disease-free patients over time in years, comparing two treatment groups labeled AC and AC+T. The chart includes a hazard ratio (HR) of 0.78 with a 95% confidence interval (0.67-0.91) and the number of events and patients at risk at various time points for each group.*

FDA Label Image

Figure 4 (Image 5)

A line graph showing the proportion surviving over a period of 4 years for two groups labeled AC and AC+T. The graph includes a table with the number of events, hazard ratio, confidence interval, and number at risk for each group, illustrating survival analysis data.*

FDA Label Image

Figure 5 (Image 6)

A survival curve chart showing the proportion of patients who are disease free over a period of 4 years. The chart compares two groups labeled AC and AC+T, displaying the number of patients at risk and events for each group along with hazard ratio and confidence interval data in an inset table.*

FDA Label Image

Figure 6 (Image 7)

A Kaplan-Meier survival curve chart showing the proportion of disease-free patients over a period of 4 years, comparing two treatment groups labeled AC and AC+T. The chart includes a table with number of patients, events, and hazard ratio with confidence intervals, as well as a risk table below the x-axis indicating patients at risk over time.*

FDA Label Image

Figure 7 (Image 8)

A line graph showing the proportion of disease-free patients over a period of four years. Two groups are compared: AC and AC+T. The graph includes a table with sample sizes, number of events, hazard ratio (HR), and confidence interval (CI) for each group. The x-axis represents years, and the y-axis represents the proportion disease-free.*

FDA Label Image

Figure 8 (Image 9)

A Kaplan-Meier survival curve chart showing the proportion of disease-free patients over four years comparing two treatment groups: AC and AC+T. The graph includes the number of participants, events, hazard ratio (HR) with 95% confidence interval, and the number at risk at each year mark for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.